Akintunde T Orunmuyi1, Sikiru A Adebayo2, Olayinka S Ilesanmi3, Augustine O Takure2, E Oluwabunmi Olapade-Olaopa2. 1. Department of Nuclear Medicine, College of Medicine, University of Ibadan and University College Hospital, Ibadan, Nigeria. 2. Department of Surgery, College of Medicine, Urology Division, University of Ibadan and University College Hospital, Ibadan, Nigeria. 3. Department of Community Medicine, College of Medicine, University of Ibadan and University College Hospital, Ibadan, Nigeria.
Abstract
Objective: There is a paucity of information on bone scanning for prostate cancer from low-resource countries. This study evaluated the role of bone scan in the primary staging of newly diagnosed prostate cancer in one such setting. Methods: A retrospective analysis of 126 men with newly diagnosed prostate cancer undergoing an initial staging bone scan between January 2017 and December 2020 was carried out at a regional nuclear medicine center in Nigeria. Bone scan results were analyzed according to age, serum level of baseline prostate-specific antigen (PSA), and Gleason score. Equivocal scans and patients with no Gleason score or baseline PSA were excluded from the analysis. p < 0.05 was said to be significant statistically. Results: Of 111 patients (aged 38-84 years, median 66 years), who met the inclusion criteria, 26 (23%) men had evidence of bony metastases as shown by a positive bone scan. Higher PSA levels and Gleason scores were associated with an increased risk of a positive bone scan, p < 0.001. No patient with a PSA level < 20 ng/mL and a Gleason score of < 7 had a positive bone scan. Conclusion: The role of bone scanning in staging newly diagnosed prostate cancer patients in Nigeria is consistent with global reports. Our study confirms that a bone scan finding is well associated with the risk classification using PSA and Gleason score in our population.
Objective: There is a paucity of information on bone scanning for prostate cancer from low-resource countries. This study evaluated the role of bone scan in the primary staging of newly diagnosed prostate cancer in one such setting. Methods: A retrospective analysis of 126 men with newly diagnosed prostate cancer undergoing an initial staging bone scan between January 2017 and December 2020 was carried out at a regional nuclear medicine center in Nigeria. Bone scan results were analyzed according to age, serum level of baseline prostate-specific antigen (PSA), and Gleason score. Equivocal scans and patients with no Gleason score or baseline PSA were excluded from the analysis. p < 0.05 was said to be significant statistically. Results: Of 111 patients (aged 38-84 years, median 66 years), who met the inclusion criteria, 26 (23%) men had evidence of bony metastases as shown by a positive bone scan. Higher PSA levels and Gleason scores were associated with an increased risk of a positive bone scan, p < 0.001. No patient with a PSA level < 20 ng/mL and a Gleason score of < 7 had a positive bone scan. Conclusion: The role of bone scanning in staging newly diagnosed prostate cancer patients in Nigeria is consistent with global reports. Our study confirms that a bone scan finding is well associated with the risk classification using PSA and Gleason score in our population.
Authors: Stephen Odunayo Ikuerowo; Olufunmilade Adefolarin Omisanjo; Muftau Jimoh Bioku; Michael Olawale Ajala; Victor Patrick Nonyelim Mordi; Julius Olusanmi Esho Journal: Pan Afr Med J Date: 2013-08-10
Authors: Jibril O Bello; Tajudeen Buhari; Taofiq O Mohammed; Hamid B Olanipekun; Arinzechukwu M Egbuniwe; Olushola K Fasiku; Rasaq Wasiu Journal: Afr Health Sci Date: 2019-03 Impact factor: 0.927
Authors: Jim Leng; Atara I Ntekim; Abiola Ibraheem; Chidinma P Anakwenze; Daniel W Golden; Olufunmilayo I Olopade Journal: JCO Glob Oncol Date: 2020-02
Authors: Tobias P Seraphin; Walburga Y Joko-Fru; Shyam S Manraj; Eric Chokunonga; Nontuthuzelo I M Somdyala; Anne Korir; Guy N'Da; Anne Finesse; Henry Wabinga; Mathewos Assefa; Freddy Gnangnon; Rolf Hansen; Nathan G Buziba; Biying Liu; Eva J Kantelhardt; Donald M Parkin Journal: Cancer Causes Control Date: 2021-07-10 Impact factor: 2.506